Screener
CRISPR Therapeutics CRSP Net margin
Net margin at other companies
Other financials
Where this comes from
Calculated from CRISPR Therapeutics’s reported figures.
Based on trailing twelve months.
The source filing: CRISPR Therapeutics’s 10-Q, filed May 4, 2026. Open the filing →
- Filed
- May 4, 2026, 4:48 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-204188
FAQ
- What is CRISPR Therapeutics's net margin?
- CRISPR Therapeutics (CRSP) reported net margin of -13,856.5% in Q1 2026.
- How has CRISPR Therapeutics's net margin changed year-over-year?
- CRISPR Therapeutics's net margin decreased by 1253.7% year-over-year, from -1,023.6% to -13,856.5%.
- What is the long-term trend for CRISPR Therapeutics's net margin?
- Over 3 years (2020 to 2025), CRISPR Therapeutics's net margin has grown at a -30.1% compound annual growth rate (CAGR), from -48,520.9% to -16,569.8%.
- What does net margin mean?
- Net income as a percentage of revenue (trailing twelve months). The bottom-line profitability measure after all costs, interest, and taxes.
Ask your AI about CRISPR Therapeutics's net margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude